MedCap Resultados de beneficios anteriores

Pasado controles de criterios 5/6

MedCap ha aumentado sus beneficios a una tasa media anual de 31.8%, mientras que los beneficios de la industria de Life Sciences han experimentado un crecimiento de 30.7% anual. Los ingresos han ido creciendo a una tasa media de 15.8% al año. La rentabilidad financiera de MedCap es de 16.8%, y sus márgenes netos son de 10.8%.

Información clave

31.8%

Tasa de crecimiento de los beneficios

30.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences	31.8%
Tasa de crecimiento de los ingresos	15.8%
Rentabilidad financiera	16.8%
Margen neto	10.8%
Próxima actualización de resultados	03 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About MedCap AB (publ) (STO:MCAP)?

Jan 22

Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

Jan 07

MedCap (STO:MCAP) Is Growing Earnings But Are They A Good Guide?

Dec 22

If You Had Bought MedCap (STO:MCAP) Stock Five Years Ago, You Could Pocket A 663% Gain Today

Dec 08

Are Insiders Selling MedCap AB (publ) (STO:MCAP) Stock?

Nov 23

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero MedCap. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:MCAP Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	1,600	172	601
30 Sep 23	1,466	150	562
30 Jun 23	1,343	149	523
31 Mar 23	1,241	123	486
31 Dec 22	1,124	118	444
30 Sep 22	1,056	118	419
30 Jun 22	1,017	107	410
31 Mar 22	967	102	394
31 Dec 21	926	97	385
30 Sep 21	896	76	375
30 Jun 21	869	64	359
31 Mar 21	845	67	339
31 Dec 20	828	63	329
30 Sep 20	802	55	326
30 Jun 20	786	53	317
31 Mar 20	763	47	308
31 Dec 19	757	55	294
30 Sep 19	734	43	288
30 Jun 19	740	41	291
31 Mar 19	727	32	297
31 Dec 18	709	24	298
30 Sep 18	716	14	286
30 Jun 18	689	8	278
31 Mar 18	660	10	268
31 Dec 17	617	7	261
31 Oct 17	779	11	298
31 Jul 17	802	3	301
30 Apr 17	853	0	299
31 Jan 17	901	5	291
31 Oct 16	897	10	276
31 Jul 16	874	19	258
30 Apr 16	818	20	239
31 Jan 16	817	18	232
31 Oct 15	818	17	226
31 Jul 15	825	8	228
30 Apr 15	855	9	228
31 Jan 15	891	9	226
31 Oct 14	913	15	221
31 Jul 14	910	21	213
30 Apr 14	827	23	203
31 Jan 14	651	18	185
31 Oct 13	517	11	176
31 Jul 13	402	17	168

Ingresos de calidad: MCAP tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (10.8%) de MCAP son superiores a los del año pasado (10.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lMCAP han crecido significativamente en un 31.8% al año.

Acelerando crecimiento: El crecimiento de los beneficios de MCAP en el último año (46.4%) supera su media de 5 años (31.8% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de MCAP en el último año (46.4%) superó al de la industria Life Sciences 46.4%.

MedCap Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025

Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)

MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024

Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)

MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024

Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)

Recent updates

MedCap AB (publ), Annual General Meeting, May 06, 2024

MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025

MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price Bounce

Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)

Investor sentiment improves as stock rises 19%

Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?

MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024

Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)

MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024

Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)

MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.

Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?

MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024

First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)

Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)

These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt Safely

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr2.47 (vs kr1.73 in 3Q 2021)

We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With Ease

Now 21% undervalued

Now 21% undervalued

MedCap AB (publ) to Report Q2, 2023 Results on Jul 28, 2023

High number of new and inexperienced directors

MedCap AB (publ) to Report Q2, 2023 Results on Jul 28, 2023

MedCap AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

High number of new and inexperienced directors

MedCap AB (publ) to Report Q1, 2023 Results on May 03, 2023

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?

MedCap AB (publ) to Report Q4, 2022 Results on Feb 10, 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MedCap (STO:MCAP) Seems To Use Debt Rather Sparingly

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

High number of new directors

Chief Executive Officer recently bought kr348k worth of stock

Investment Manager recently bought kr828k worth of stock

Third quarter 2021 earnings released: EPS kr1.73 (vs kr0.89 in 3Q 2020)

Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

Second quarter 2021 earnings released: EPS kr1.06 (vs kr1.33 in 2Q 2020)

Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Independent Chairman of the Board recently bought kr1.1m worth of stock

Here's Why I Think MedCap (STO:MCAP) Is An Interesting Stock

Imagine Holding MedCap (STO:MCAP) Shares While The Price Zoomed 558% Higher

Have Insiders Been Selling MedCap AB (publ) (STO:MCAP) Shares?

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS kr4.36 (vs kr4.10 in FY 2019)

New 90-day low: kr193

MedCap (STO:MCAP) Could Easily Take On More Debt

Declining Stock and Solid Fundamentals: Is The Market Wrong About MedCap AB (publ) (STO:MCAP)?

An unknown buyer acquired 10.1% stake in MedCap AB (publ) (OM:MCAP) from Bure Equity AB (publ) (OM:BURE).

Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

MedCap (STO:MCAP) Is Growing Earnings But Are They A Good Guide?

If You Had Bought MedCap (STO:MCAP) Stock Five Years Ago, You Could Pocket A 663% Gain Today

Market bids up stock over the past week

New 90-day high: kr233

Are Insiders Selling MedCap AB (publ) (STO:MCAP) Stock?

Revenue and earnings miss expectations

Third quarter 2020 earnings released: EPS kr0.89

New 90-day high: kr227

New 90-day high - kr207

MedCap AB (publ) to Report Q2, 2021 Results on Jul 30, 2021

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Desglose de ingresos y gastos
Beta